Carol Meschter, DVM, PhD, DACVP
Chief Executive Officer

Dr. Carol Meschter is one of the original founders of Comparative Biosciences. Previously, she was in the Investigative Toxicology Group at Hoffmann-LaRoche in Nutley, N.J., and was the director of the Research Animal Facility at the American Health Foundation in Valhalla, N.Y. As a board-certified veterinary pathologist, Dr. Meschter brings 15 years of experience in the pharmaceutical industry, primarily in toxicology, pathology, preclinical development, discovery support and preclinical pharmacology. Knowledgeable about early-phase drug development from discovery to new drug application, she has technical expertise in pathology, pharmacology, efficacy modeling and pharmacokinetics. Dr. Meschter is a scientific editorial reviewer for Toxicologic Pathology, Veterinary Pathology, AVMA Journal, AJVR, J Applied Immunology and has over 100 publications.

James Christenson, PhD
Senior Vice President

Dr. James Christenson, senior vice president, previously was director of antibacterial research and international project director at Hoffmann-LaRoche in Nutley, N.J., and executive director of project management at Microcide Pharmaceuticals, Inc., in Mountain View, Calif. Dr. Christenson has over 30 years of experience in the pharmaceutical and contract research industries, primarily in anti-infective drug discovery and development including all phases of drug development from discovery to post-marketing. He has extensive technical expertise in pharmacokinetics, toxicology, biochemistry, microbiology, assay development and animal models. He has over 75 publications and patents, and is a scientific editorial reviewer for peer-reviewed publications that include Antimicrobial Agents and Chemotherapy and Clinical and Diagnostic Laboratory Immunology.

For more information on Dr. Christenson’s antibacterial experience or for a consultation, please visit

Darren Warren, PhD
Vice President of Scientific Studies and Operations

Dr. Darren Warren joined Comparative Biosciences as vice president in early 2016. With over 25 years of industry experience, he has a broad background in nonclinical pharmaceutical development of both small and large molecules that includes scientific, technical, project management and strategic responsibilities both in large pharma and at various contract research organizations (CROs). He also has broad experience in operational leadership of nonclinical CROs and has a record of accomplishment in facilitating efficient completion of studies and research programs. Dr. Warren understands the value of the client-CRO relationship and applies creativity, know-how and collaboration to always exceed expectations.

Douglas S. Crowder, BS
Director of Business Development

Mr. Douglas Crowder joined Comparative Biosciences’ business development team in 2014. His experience with clinical medical professionals and business-to-business sales has merged with his education, a Bachelor of Science in biology with an emphasis in physiology in anatomy, helping him reach a record pace year for client growth and expansion at CBI. He is a champion for his clients, helping them reach their preclinical research goals in their efforts toward medical advancement, which provides him his greatest personal reward. His passion and knowledge strongly align with CBI’s dedication to provide industry-leading service and quality to new and existing customers alike through individualized planning, clear communication and efficient execution.

Allyson Lageschulte, MA
Corporate Controller

Ms. Allyson Lageschulte joined Comparative Biosciences’ finance team in February 2014 as the financial controller. Prior to joining CBI, she worked as the controller/vice president of finance for Soliddd Corp. for over four years. She has over 20 years of experience working in different industries in the Silicon Valley, mostly for small, privately held startup firms. Holding both bachelor’s and master’s degrees in economics, her background includes finance, facilities and human resources, and her expertise is in building and improving company infrastructure.